|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.66/-1.19
|
企业价值
244.40M
|
资产负债 |
每股账面净值
0.75
|
现金流量 |
现金流量率
--
|
损益表 |
收益
3.09M
|
每股收益
0.05
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 11:25 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S. |